'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials
Moderna emerged as an early leader in the race for a vaccine to stop Covid-19 in its tracks. The Cambridge, Massachusetts-based biotech bounded through development of one of the world’s first mRNA vaccines, but in September — when the pandemic was claiming upwards of 700 lives a day in the US — they took a step back.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.